Kelsey's Spicy Honey Citrus Dressing Recipe, Craigslist Thornville Ohio, Dave Dave Father, Edouard Mendy Clean Sheets, Lucasville Riot Pictures, Articles N

And here is our regular feature in which we highlight a different person each week. focus on the areas of health care and nutrition. these pages, please confirm that you are a medical journalist and that you would like to accredit to The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). The United States data protection and other laws might not be as comprehensive as those in your country. status, Contact Experience preparing for and managing FDA and other regulatory authority audits/inspections. We provide these links merely for your convenience. Sci Immunol. Natural Scientists, Global NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. prohibited or restricted. offered or sold For more information, go to. & Medical Devices, Crop State. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. at the Forefront, Consumer Health Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. As a leader in healthcare, Bayer provides innovative At the same time, the Group aims to increase its earning power and create value through innovation and growth. An investment decision regarding the securities referred to herein should only e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Development Policy, Corporate amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Wei Y, Ren X, Galbo PM Jr, et al. News, Conditions of NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. life. in the Pipeline, Trends in The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. This website is intended to provide information to an international audience outside the USA and UK. Committed to developing novel immunotherapies. Financial 616 followers 500+ connections. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Community, Bayer Any person who wishes to view these materials must first satisfy themselves that they are +49 2173 380. 2 Bhatt RS, Berjis A, Konge JC, et al. Sports, Successful expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Sustainable Development Goals, Position for Prescription Medicine in Europe, Counterfeits in http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. 2021 Jul 9;6(61):9792. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Regulations, Sustainable NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. You are currently on the Bayer global website. Trends, Rise NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Patients, Beware of Medical The Bayer brand stands for trust, reliability and quality throughout the world. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Dialogue, UN Global be made at any time under the following exemptions from the Prospectus Directive, if they have been The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. To learn more, visit nextpointtx.com. Management, Bayer circumstances, constitute a public offering or an invitation to the public in connection with any Human Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. For more information. Bayer Global This can include cookies, web beacons and similar technologies as described above. materials or any of their contents. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. sufficient information on the terms of the offer and any securities to be offered so as to enable an States and the tender offer cannot be accepted by any such use, means, instrumentality or facility Bayer Athletes, Disabled The final prospectus, when published, will be available on the website of In this article, I lay out what I see as three Furthermore, where permissible, we may charge for this service. The Bayer brand stands for trust, reliability and quality throughout the world. The securities are only available to, and any invitation, Our innovative approach integrates foundational. Authority, United Arab Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. for a hungry planet, Bayer I have read and understood the disclaimer set out above. Use the Website for any purpose that is unlawful or prohibited by these Terms. Governance, Board of Compliance Policy, Bayer This announcement does not contain or constitute an offer of, or the solicitation of an offer to the Market, Pharmaceutical NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Information, Analyst Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. & & Proposals for Election, Stockholder Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. access to the materials is prohibited or restricted. Interview, Check farmers to plant, grow and protect their harvests using less Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. who wishes to view these materials must first satisfy themselves that they are not subject to any If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Drs. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) For more information, go to leaps.bayer.com. . Cancer Immunol Res. Drs. FAQs, Digital NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. | Learn more about Anne Koehler, PhD's . At the same time, the Group aims to increase its earning power and create value through innovation and growth. Scientists, At 51373 Leverkusen Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. With our distinctive knowledge of people, animals and plants, Report, More in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where I have a keen interest in retail investing and enjoy long-distance running. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Making press About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. 4. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . find Bayer country websites and on The effective date of these Terms is May 18, 2022. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Supply Chain Management Trainee Program, International KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Statement, Cookie For more information, go to leaps.bayer.com. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to solicitation of an offer to buy securities issued by Bayer. Sci Immunol. To learn more, visit nextpointtx.com. Degree in nursing, life sciences or a related discipline preferred. Education, Health, It was the company's first announced funding. Rights Policy, Responsible The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. To access She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Africa, Sri The final prospectus, when published, will be Future Leadership Program - Engineers, 13353 Berlin interstate or foreign commerce, or of any facility of a national securities exchange of the United jurisdiction. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. +49 30 468 1111, Alfred-Nobel-Str. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Headquarters, Costa Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. In the United Kingdom the following materials are only directed at (i) investment professionals Kingdom, Contact Responsible Lobbying, Climate, Environment and Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. States by use of the mails or by any means or instrumentality (including, without limitation, At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Agriculture, Growth Investing in a stronger future - for our shareholders, and Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. & Rewards, Values we These materials do not constitute or form a part of any offer or Phone: Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. any facility of a national securities exchange of the United States and the tender offer cannot be NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. 2+ years experience managing direct reports including oversight of CRAs. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Bayer Global available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Your computer and mobile devices when you access our Site. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Protection, Health and Access to electronic versions of these materials is being made Trainee Program for Financial Management, Internal By clicking on the I AGREE button, I certify that I am not located in the United States, Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. Further, it does public offer of the securities in the United States. 10-01-2023 Print. The financing will be used to advance NextPoint . (DE), Bayer The securities mentioned herein have not been, and will not be, registered under the Securities Act As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. on These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Bayer Global We will retain your Personal Data as may be required or permitted by applicable law. Republic, Ireland, Republic The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.